Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7754183 | 1.00 | LMNA (0.59) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL445888 | 0.98 | LMNA (0.55) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL8812570 | 0.84 | LMNA (0.39) | LMNABLM | |
| SCHEMBL8812227 | 0.84 | LMNA (0.39) | LMNABLM | |
| SCHEMBL14778126 | 0.81 | LMNA (0.48) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL14777945 | 0.81 | LMNA (0.59) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL1827120 | 0.81 | LMNA (0.59) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL8672325 | 0.79 | LMNA (0.93) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL538230 | 0.79 | LMNA (0.93) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL20928 | 0.79 | LMNA (0.93) | LMNABLMPTPN1MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0688555-A2 | Hair-growing agent | TANABE SEIYAKU CO., LTD. (JP) | 1995-12-27 | — | — | EP | claimed |
| US-12016929-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-25 | — | — | US | disclosed |
| US-20240182895-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-06 | — | — | US | disclosed |
| US-20240148875-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-05-09 | — | — | US | disclosed |
| US-20240100166-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-03-28 | — | — | US | disclosed |
| WO-2024026353-A2 | ENZYMATIC SYNTHESIS OF MYCOSPORINE-LIKE AMINO ACIDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20240035030-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-02-01 | — | — | US | disclosed |
| US-11786598-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-10-17 | — | — | US | disclosed |
| CN-111481469-B | copolymer | 宝丽化学工业有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-111358713-B | copolymer | 宝丽化学工业有限公司 | 2023-09-19 | — | — | CN | disclosed |
| EP-1409551-A4 | CHIMERIC CAPSID PROTEINS AND USES THEREOF | UAB RESEARCH FOUNDATION (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2004060912-A2 | CHIMERIC CAPSID PROTEINS AND EXPRESSION VECTORS FOR MONOCISTRONIC EXPRESSION OF MULTIPLE GENES | UAB RESEARCH FOUNDATION (US) | 2004-07-22 | — | — | WO | disclosed |
| EP-1409551-A2 | CHIMERIC CAPSID PROTEINS AND USES THEREOF | UAB RESEARCH FOUNDATION (US) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003000855-A2 | CHIMERIC CAPSID PROTEINS AND USES THEREOF | UAB RESEARCH FOUNDATION (US) | 2003-01-03 | — | — | WO | disclosed |
| EP-0670317-B9 | EPOXYCYCLOHEXENEDIONE DERIVATIVE | KYOWA HAKKO KOGYO KK (JP) | 2001-03-14 | — | — | EP | disclosed |
| EP-0670317-B1 | EPOXYCYCLOHEXENEDIONE DERIVATIVE | KYOWA HAKKO KOGYO KK (JP) | 2000-03-08 | — | — | EP | disclosed |
| US-5741816-A | CARNITINE COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 1998-04-21 | — | — | US | disclosed |
| US-5565489-A | MICROBIOCIDES, ANTITUMOR AGENTS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1996-10-15 | — | — | US | disclosed |
| EP-0688555-A2 | Hair-growing agent | TANABE SEIYAKU CO., LTD. (JP) | 1995-12-27 | — | — | EP | disclosed |
| EP-0670317-A1 | EPOXYCYCLOHEXENEDIONE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1995-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100166-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | PNLIP, NPC1L1, CETP | LMNA 758/4885BLM 2897/4885PTPN1 2028/4885 |
| US-20240182895-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | LMNA 177/4885BLM 1596/4885PTPN1 1636/4885 |
| US-20240148875-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | PNLIP, NPC1L1, CETP | LMNA 758/4885BLM 2897/4885PTPN1 2028/4885 |
| US-20240035030-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | LMNA 177/4885BLM 1596/4885PTPN1 1636/4885 |
| US-11786598-B2 | Lipid formulations for delivery of therapeutic agents | CETP, PNLIP, NPC1L1 | LMNA 793/4885BLM 3014/4885PTPN1 1747/4885 |
| US-12016929-B2 | Lipid formulations for delivery of therapeutic agents | CETP, PNLIP, NPC1L1 | LMNA 793/4885BLM 3014/4885PTPN1 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.